Clinical implications for cediranib in advanced cervical cancer.

James Cripe, Krishnansu S Tewari, Fong W Liu, Anti-angiogenesis therapy in gynecologic malignancies. Oncology. ,vol. 29, pp. 350- 360 ,(2015)

Richard T Penson, Helen Q Huang, Lari B Wenzel, Bradley J Monk, Sharon Stockman, Harry J Long, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J A Reid, Mario M Leitao, Michael Method, Helen Michael, Krishnansu S Tewari, Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240) The Lancet Oncology. ,vol. 16, pp. 301- 311 ,(2015) , 10.1016/S1470-2045(15)70004-5

Ramez N. Eskander, Krishnansu S. Tewari, Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications Gynecologic Oncology. ,vol. 132, pp. 496- 505 ,(2014) , 10.1016/J.YGYNO.2013.11.029

Lindsey E. Minion, Jiaru Bai, Bradley J. Monk, L. Robin Keller, Eskander N. Ramez, Gareth K. Forde, John K. Chan, Krishnansu S. Tewari, A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer Gynecologic Oncology. ,vol. 137, pp. 490- 496 ,(2015) , 10.1016/J.YGYNO.2015.02.027

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas J. Reid, Mario M. Leitao, Helen E. Michael, Bradley J. Monk, Improved Survival with Bevacizumab in Advanced Cervical Cancer The New England Journal of Medicine. ,vol. 370, pp. 734- 743 ,(2014) , 10.1056/NEJMOA1309748

Ryo Kitagawa, Noriyuki Katsumata, Taro Shibata, Toshiharu Kamura, Takahiro Kasamatsu, Toru Nakanishi, Sadako Nishimura, Kimio Ushijima, Masashi Takano, Toyomi Satoh, Hiroyuki Yoshikawa, Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505 Journal of Clinical Oncology. ,vol. 33, pp. 2129- 2135 ,(2015) , 10.1200/JCO.2014.58.4391

R Paul Symonds, Charlie Gourley, Susan Davidson, Karen Carty, Elaine McCartney, Debbie Rai, Susana Banerjee, David Jackson, Rosemary Lord, Mary McCormack, Emma Hudson, Nicholas Reed, Maxine Flubacher, Petra Jankowska, Melanie Powell, Caroline Dive, Catharine M L West, James Paul, Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial Lancet Oncology. ,vol. 16, pp. 1515- 1524 ,(2015) , 10.1016/S1470-2045(15)00220-X

Bradley J. Monk, Luis Mas Lopez, Juan J. Zarba, Ana Oaknin, Carole Tarpin, Wichai Termrungruanglert, Jacquelyn A. Alber, Jie Ding, Melissa W. Stutts, Lini N. Pandite, Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer Journal of Clinical Oncology. ,vol. 28, pp. 3562- 3569 ,(2010) , 10.1200/JCO.2009.26.9571

Bradley J. Monk, Michael W. Sill, Robert A. Burger, Heidi J. Gray, Thomas E. Buekers, Lynda D. Roman, Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 27, pp. 1069- 1074 ,(2009) , 10.1200/JCO.2008.18.9043

Eunice Lee Kwak, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel Virgil Thomas Catenacci, Emily Chan, Tanios S. Bekaii-Saab, Benny Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, David S. Hong, Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. Journal of Clinical Oncology. ,vol. 33, pp. 1- 1 ,(2015) , 10.1200/JCO.2015.33.3_SUPPL.1